Development of Less Toxic Treatment Strategies for Metastatic and Drug-Resistant Breast Cancer Using Noninvasive Optical Monitoring
Technical Report,01 Sep 2016,31 Aug 2017
Boston University Boston United States
Pagination or Media Count:
This project involves the development of optically guided multi-agent therapies for metastatic and drug resistant breast cancer. Non-invasive Diffuse Optical Imaging technologies are able to monitor drug response and resistance through quantitative tracking of tumor metabolism and vascular supply, using clinic friendly and portable devices that can monitor deep lesions multiple centimeters below the skin in both breast tissue and at the site of bone metastases. During year 2 of the project wehave make substantial improvements and advancements in our small imaging technologies, including hyperspectral SFDI and long-wavelength SFDI. The growth rates and feasibility of use of several breast cancer cell-linestumor models has been evaluated, with one good option, the Py230 cell lines, as our choice for use in future studies. We have conducted the first study using combined SFDI and multiphoton intravital imaging in a mouse mammary tumor model. Development of a clinical imaging platform has also progressed. Two publications, numerous seminar talks and conference talks and posters have been delivered over the past year to disseminate the work conducted in this award.
- Medicine and Medical Research